U-CH7 (ATCC® CRL-3404)

Organism: Homo sapiens, human  /  Tissue: sacral bone  /  Disease: primary tumor

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue sacral bone
Product Format frozen 1.0 mL
Morphology fibroblast-like
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease primary tumor
Age 33 years old
Gender male
Ethnicity White
Applications
In vitro cell culture model for analysis of tumorigenesis in chordoma cell lines. Useful in predicting the clinical performance of cancer drugs

The Chordoma Foundation may be able to offer financial assistance for the purchase of this cell line. Please contact cells@chordoma.org for more information.
Storage Conditions liquid nitrogen vapor phase
Complete Growth Medium

The base medium for this cell line is Iscove's Modified Dulbecco's Medium (IMDM; ATCC 30-2005): RPMI-1640 Medium (ATCC 30-2001) at a 4 to 1 ratio. To 500 mL IMDM:RPMI 1640 (4:1) add the following components to make the complete medium:

  • 56 mL  FBS (ATCC 30-2020), final concentration of 10%
  • 5.6 mL L-glutamine from stock 200 mM (ATCC 30-2214), final concentation of 1%
Subculturing
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
    Cultures can be established between 2.0 x 104 and 6.0 x 104 viable cells/cm2.
  6. Incubate cultures at 37°C.
Interval: Maintain cultures at a cell concentration between 2 X 104 and 1.6 X 105 cell/cm2.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation Culture medium + 5% DMSO (ATCC 4-X)
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Cells per Vial Approximately 2.5 to 3.5 x 106 cells
Volume 1.0 mL
STR Profile
Amelogenin: X,Y
CSF1PO: 12
D13S317: 10
D16S539: 10,12
D5S818: 12,13
D7S820: 10,11
THO1: 7
TPOX: 8,11
vWA: 16,17
Sterility Tests Bacteria and yeast: No growth
Mycoplasma: No growth
Viral Testing Hepatitis B: None detected
Cytomegalovirus: None detected
Human immunodeficiency virus: None detected
Epstein-Barr virus: None detected
Human papillomavirus: None detected
Name of Depositor P Moller, University of Ulm, Institute of Pathology
Year of Origin 2011
References

von Witzleben A, et al. Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell-cycle pathway. Cancer Res 75(18): 3823-31. PubMed: 26183925

Bruderlein S, et al. Molecular characterization of putative chordoma cell lines. Sarcoma 2010: 630129. Epub 2010 Dec 30. PubMed: 21253487

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

von Witzleben A, et al. Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell-cycle pathway. Cancer Res 75(18): 3823-31. PubMed: 26183925

Bruderlein S, et al. Molecular characterization of putative chordoma cell lines. Sarcoma 2010: 630129. Epub 2010 Dec 30. PubMed: 21253487